Summary

HNY Research projects that the Radiopharmaceuticals in Nuclear Medicine market size will grow from 6811.56 Million USD in 2025 to 11034.45 Million USD by 2031, at an estimated CAGR of 8.37%. The base year considered for the study is 2025, and the market size is projected from 2026 to 2031.This report presents a detailed and holistic analysis of the global Radiopharmaceuticals in Nuclear Medicine market. It integrates quantitative data with qualitative insights to equip readers with the necessary information for strategic planning, competitive assessment, market positioning, and data-driven decision-making.
All market sizes, estimates, and forecasts are expressed in terms of output/shipments and revenue. With 2025 serving as the base year, the report provides historical context from 2020. and projections up to 2031. It includes a complete segmentation of the global market, along with regional market sizes analyzed by type, application, and key industry participants.
Further enriching the analysis, the report outlines the competitive environment, offering profiles of prominent players and their market standings. It also explores key technological advancements and recent developments in product offerings.
Ultimately, this report serves as a vital resource for Radiopharmaceuticals in Nuclear Medicine manufacturers, prospective entrants, and other stakeholders within the industry value chain. It supplies comprehensive data on revenues, production, and average pricing for the overall market and its sub-segments, detailed by company, product type, application, and geographic region.

By Market Players:
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Dongcheng

By Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals

By Application
Oncology
Cardiology
Other

By Regions/Countries:
North America
East Asia
Europe
South Asia
Southeast Asia
Middle East
Africa
Oceania
South America

Points Covered in The Report
The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.
The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.
Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.
The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Radiopharmaceuticals in Nuclear Medicine Revenue
1.4 Market Analysis by Type
1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Type: 2026-2031
1.4.2 Diagnostic Radiopharmaceuticals
1.4.3 Therapy Radiopharmaceuticals
1.5 Market by Application
1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application: 2026-2031
1.5.2 Oncology
1.5.3 Cardiology
1.5.4 Other
1.6 Study Objectives
1.7 Overview of Global Radiopharmaceuticals in Nuclear Medicine Market
1.7.1 Global Radiopharmaceuticals in Nuclear Medicine Market Status and Outlook (2020-2031)
1.7.2 North America
1.7.3 East Asia
1.7.4 Europe
1.7.5 South Asia
1.7.6 Southeast Asia
1.7.7 Middle East
1.7.8 Africa
1.7.9 Oceania
1.7.10 South America
1.7.11 Rest of the World
2 Manufacturing Cost Structure Analysis
2.1 Manufacturing Cost Structure Analysis of Radiopharmaceuticals in Nuclear Medicine
2.2 Industry Chain Structure of Radiopharmaceuticals in Nuclear Medicine
3 Market Competition by Manufacturers
3.1 Global Radiopharmaceuticals in Nuclear Medicine Production Capacity Market Share by Manufacturers (2020-2025)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2020-2025)
3.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2020-2025)
4 Radiopharmaceuticals in Nuclear Medicine Regional Market Analysis
4.1 Radiopharmaceuticals in Nuclear Medicine Production by Regions
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Production by Regions (2020-2025)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Regions
4.2 Radiopharmaceuticals in Nuclear Medicine Consumption by Regions
4.3 North America Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.3.1 North America Radiopharmaceuticals in Nuclear Medicine Production
4.3.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue
4.3.3 Key Manufacturers in North America
4.3.4 North America Radiopharmaceuticals in Nuclear Medicine Import and Export
4.4 East Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.4.1 East Asia Radiopharmaceuticals in Nuclear Medicine Production
4.4.2 East Asia Radiopharmaceuticals in Nuclear Medicine Revenue
4.4.3 Key Manufacturers in East Asia
4.4.4 East Asia Radiopharmaceuticals in Nuclear Medicine Import & Export
4.5 Europe Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.5.1 Europe Radiopharmaceuticals in Nuclear Medicine Production
4.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue
4.5.3 Key Manufacturers in Europe
4.5.4 Europe Radiopharmaceuticals in Nuclear Medicine Import & Export
4.6 South Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.6.1 South Asia Radiopharmaceuticals in Nuclear Medicine Production
4.6.2 South Asia Radiopharmaceuticals in Nuclear Medicine Revenue
4.6.3 Key Manufacturers in South Asia
4.6.4 South Asia Radiopharmaceuticals in Nuclear Medicine Import & Export
4.7 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.7.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Production
4.7.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Revenue
4.7.3 Key Manufacturers in Southeast Asia
4.7.4 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Import & Export
4.8 Middle East Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.8.1 Middle East Radiopharmaceuticals in Nuclear Medicine Production
4.8.2 Middle East Radiopharmaceuticals in Nuclear Medicine Revenue
4.8.3 Key Manufacturers in Middle East
4.8.4 Middle East Radiopharmaceuticals in Nuclear Medicine Import & Export
4.9 Africa Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.9.1 Africa Radiopharmaceuticals in Nuclear Medicine Production
4.9.2 Africa Radiopharmaceuticals in Nuclear Medicine Revenue
4.9.3 Key Manufacturers in Africa
4.9.4 Africa Radiopharmaceuticals in Nuclear Medicine Import & Export
4.10 Oceania Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.10.1 Oceania Radiopharmaceuticals in Nuclear Medicine Production
4.10.2 Oceania Radiopharmaceuticals in Nuclear Medicine Revenue
4.10.3 Key Manufacturers in Oceania
4.10.4 Oceania Radiopharmaceuticals in Nuclear Medicine Import & Export
4.11 South America Radiopharmaceuticals in Nuclear Medicine Market Analysis
4.11.1 South America Radiopharmaceuticals in Nuclear Medicine Production
4.11.2 South America Radiopharmaceuticals in Nuclear Medicine Revenue
4.11.3 Key Manufacturers in South America
4.11.4 South America Radiopharmaceuticals in Nuclear Medicine Import & Export
5 Radiopharmaceuticals in Nuclear Medicine Sales Market by Type (2020-2031)
5.1 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Type (2020-2025)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Type (2026-2031)
6 Radiopharmaceuticals in Nuclear Medicine Consumption Market by Application(2020-2031)
6.1 Global Radiopharmaceuticals in Nuclear Medicine Historic Market Size by Application (2020-2025)
6.2 Global Radiopharmaceuticals in Nuclear Medicine Forecasted Market Size by Application (2026-2031)
7 Company Profiles and Key Figures in Radiopharmaceuticals in Nuclear Medicine Business
7.1 Cardinal Health
7.1.1 Cardinal Health Company Profile
7.1.2 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Specification
7.1.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.2 GE Healthcare
7.2.1 GE Healthcare Company Profile
7.2.2 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Specification
7.2.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.3 Jubilant Pharma
7.3.1 Jubilant Pharma Company Profile
7.3.2 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Specification
7.3.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.4 Novartis
7.4.1 Novartis Company Profile
7.4.2 Novartis Radiopharmaceuticals in Nuclear Medicine Product Specification
7.4.3 Novartis Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.5 Curium Pharma
7.5.1 Curium Pharma Company Profile
7.5.2 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Specification
7.5.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.6 SIEMENS
7.6.1 SIEMENS Company Profile
7.6.2 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Specification
7.6.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.7 Lantheus
7.7.1 Lantheus Company Profile
7.7.2 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Specification
7.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.8 Bracco Imaging
7.8.1 Bracco Imaging Company Profile
7.8.2 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Specification
7.8.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.9 Bayer
7.9.1 Bayer Company Profile
7.9.2 Bayer Radiopharmaceuticals in Nuclear Medicine Product Specification
7.9.3 Bayer Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.10 Eli Lilly
7.10.1 Eli Lilly Company Profile
7.10.2 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Specification
7.10.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.11 Aurobindo Pharma
7.11.1 Aurobindo Pharma Company Profile
7.11.2 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Specification
7.11.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.12 Mundipharma
7.12.1 Mundipharma Company Profile
7.12.2 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Specification
7.12.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.13 China Isotope & Radiation
7.13.1 China Isotope & Radiation Company Profile
7.13.2 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Specification
7.13.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
7.14 Dongcheng
7.14.1 Dongcheng Company Profile
7.14.2 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Specification
7.14.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2020-2025)
8 Production and Supply Forecast
8.1 Global Forecasted Production of Radiopharmaceuticals in Nuclear Medicine (2026-2031)
8.2 Global Forecasted Revenue of Radiopharmaceuticals in Nuclear Medicine (2026-2031)
8.3 Global Forecasted Price of Radiopharmaceuticals in Nuclear Medicine (2020-2031)
8.4 Global Forecasted Production of Radiopharmaceuticals in Nuclear Medicine by Region (2026-2031)
8.4.1 North America Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.2 East Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.3 Europe Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.4 South Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.5 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.6 Middle East Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.7 Africa Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.8 Oceania Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.9 South America Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.4.10 Rest of the World Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2026-2031)
8.5 Forecast by Type and by Application (2026-2031)
8.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2026-2031)
8.5.2 Global Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Application (2026-2031)
9 Consumption and Demand Forecast
9.1 North America Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.2 East Asia Market Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.3 Europe Market Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Countriy
9.4 South Asia Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.5 Southeast Asia Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.6 Middle East Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.7 Africa Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.8 Oceania Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.9 South America Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
9.10 Rest of the world Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
10 Marketing Channel, Distributors and Customers
10.1 Marketing Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
11 Market Dynamics
11.1 Market Trends
11.2 Opportunities and Drivers
11.3 Challenges
11.4 Porter's Five Forces Analysis
12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer